These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

827 related articles for article (PubMed ID: 19331437)

  • 1. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
    Ansquer JC; Bekaert I; Guy M; Hanefeld M; Simon A;
    Am J Cardiovasc Drugs; 2009; 9(2):91-101. PubMed ID: 19331437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.
    Farnier M; Taggart W; Dong Q; Lin J; Shah A; Brudi P
    J Clin Lipidol; 2011; 5(3):179-187. PubMed ID: 21600523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
    Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B
    Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Macdonell G; Taggart WV; Gumbiner B
    Metab Syndr Relat Disord; 2011 Apr; 9(2):135-42. PubMed ID: 21117970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.
    Kosoglou T; Statkevich P; Fruchart JC; Pember LJ; Reyderman L; Cutler DL; Guillaume M; Maxwell SE; Veltri EP
    Curr Med Res Opin; 2004 Aug; 20(8):1197-207. PubMed ID: 15324522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
    Steinmetz A; Schwartz T; Hehnke U; Kaffarnik H
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of a "suprabioavailable" formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.
    Ramjattan BR; Callaghan DJ; Theiss U
    Clin Ther; 2002 Jul; 24(7):1105-16. PubMed ID: 12182255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy.
    Grandi AM; Nicolini E; Rizzi L; Caputo S; Annoni F; Cremona AM; Marchesi C; Guasti L; Maresca AM; Grossi P
    J Int AIDS Soc; 2014; 17(1):19004. PubMed ID: 25148829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial.
    Ihm SH; Chung WB; Lee JM; Hwang BH; Yoo KD; Her SH; Song WH; Chae IH; Park TH; Kim JH; Jeon DW; Cho BR; Kang SH; Park SD; Lee JB; Woo JT; Lee BW; Han KA; Won KH; Kim HS; Yu JM; Chung CH; Kim HJ; Cho HC; Seung KB
    Clin Ther; 2020 Oct; 42(10):2021-2035.e3. PubMed ID: 32891418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
    Kerzner B; Corbelli J; Sharp S; Lipka LJ; Melani L; LeBeaut A; Suresh R; Mukhopadhyay P; Veltri EP;
    Am J Cardiol; 2003 Feb; 91(4):418-24. PubMed ID: 12586255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
    Gaudiani LM; Lewin A; Meneghini L; Perevozskaya I; Plotkin D; Mitchel Y; Shah S
    Diabetes Obes Metab; 2005 Jan; 7(1):88-97. PubMed ID: 15642080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.
    Huijgen R; Abbink EJ; Bruckert E; Stalenhoef AF; Imholz BP; Durrington PN; Trip MD; Eriksson M; Visseren FL; Schaefer JR; Kastelein JJ;
    Clin Ther; 2010 Apr; 32(4):615-25. PubMed ID: 20435231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.